Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04+00:00February 14th, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11+00:00January 31st, 2017|2017 プレスリリース, プレスリリース| 続きを読む
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23+00:00November 14th, 2016|2016 プレスリリース, プレスリリース| 続きを読む
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Developmentwmm2021-02-26T19:14:30+00:00May 31st, 2016|2016 プレスリリース, プレスリリース| 続きを読む
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37+00:00March 28th, 2016|2016 プレスリリース, プレスリリース| 続きを読む
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)wmm2021-02-26T19:14:49+00:00February 18th, 2016|2016 プレスリリース, プレスリリース| 続きを読む
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientificwmm2021-02-26T19:15:19+00:00February 9th, 2016|2016 プレスリリース, プレスリリース| 続きを読む
Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutationswmm2021-02-26T19:16:48+00:00December 5th, 2015|Archived プレスリリース, プレスリリース| 続きを読む
